A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease "ANITA"
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Nintedanib (Primary) ; Ifosfamide
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms ANITA
- 10 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2016 New trial record